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Macfarlane DP, Raubenheimer PJ, Preston T, Gray CD, Bastin
ME, Marshall I, Iredale JP, Andrew R, Walker BR. Effects of
acute glucocorticoid blockade on metabolic dysfunction in patients
with Type 2 diabetes with and without fatty liver. Am J Physiol
Gastrointest Liver Physiol 307: G760–G768, 2014. First published
August 7, 2014; doi:10.1152/ajpgi.00030.2014.—To investigate the
potential of therapies which reduce glucocorticoid action in patients
with Type 2 diabetes we performed a randomized, double-blinded,
placebo-controlled crossover study of acute glucocorticoid blockade,
using the glucocorticoid receptor antagonist RU38486 (mifepristone)
and cortisol biosynthesis inhibitor (metyrapone), in 14 men with Type
2 diabetes. Stable isotope dilution methodologies were used to mea-
sure the rates of appearance of glucose, glycerol, and free fatty acids
(FFAs), including during a low-dose (10 mU·m 2·min1) hyperin-
sulinemic clamp, and subgroup analysis was conducted in patients
with high or low liver fat content measured by magnetic resonance
spectroscopy (n  7/group). Glucocorticoid blockade lowered fasting
glucose and insulin levels and improved insulin sensitivity of FFA and
glycerol turnover and hepatic glucose production. Among this popu-
lation with Type 2 diabetes high liver fat was associated with hyper-
insulinemia, higher fasting glucose levels, peripheral and hepatic
insulin resistance, and impaired suppression of FFA oxidation and
FFA and glycerol turnover during hyperinsulinemia. Glucocorticoid
blockade had similar effects in those with and without high liver fat.
Longer term treatments targeting glucocorticoid action may be useful
in Type 2 diabetes with and without fatty liver.
nonalcoholic fatty liver disease; Type 2 diabetes; glucocorticoids;
fatty acid metabolism
GLUCOCORTICOIDS, PRINCIPALLY cortisol in humans and cortico-
sterone in rodents, play a key role in regulating substrate
availability and cellular energy balance (1, 25). However,
although promoting lipolysis in adipose tissue and gluconeo-
genesis in liver may promote survival in times of acute stress
or starvation, in the longer term, prolonged exposure to excess
glucocorticoids may be maladaptive, with adverse metabolic
consequences including the development of Type 2 diabetes (7,
41). Glucocorticoids promote hyperglycemia via a number of
mechanisms: impairing insulin secretion (18), modulating glu-
cose delivery to tissues (26), and inducing hepatic and periph-
eral insulin resistance (34). In addition, the metabolic conse-
quences of glucocorticoids on fatty acid metabolism are likely
to be highly dependent on prevailing insulin levels (8), such
that relative insulin deficiency, as seen in Type 2 diabetes, may
lead to more pronounced abnormalities of fatty acid metabo-
lism, potentially exacerbating the contribution of glucocortico-
ids to peripheral insulin resistance (4).
Rodent studies suggest that modulation of glucocorticoid
receptor activation may influence hepatic triglyceride accumu-
lation (20, 23, 32) and the development of nonalcoholic fatty
liver disease (NAFLD), a common feature in Type 2 diabetes
(42). NAFLD is widely regarded as the hepatic manifestation
of the metabolic syndrome (27) and is associated with hepatic
insulin resistance (16), although it is unclear whether this
represents a primary or secondary phenomenon (6). Metabolic
tracer studies in nondiabetic individuals with NAFLD suggest
insulin resistance in adipose tissue may drive the development
of NAFLD, leading to increased release of free fatty acids
(FFAs) and glycerol into the circulation, and promoting the
accumulation of adipose-derived FFAs within the liver (5, 11).
Glucocorticoids modulate these key pathways, but it is un-
known whether abnormalities of glucocorticoid signaling ex-
acerbate the development of NAFLD in Type 2 diabetes.
There is evidence that glucocorticoid receptor activation can
be reduced selectively and safely within liver and adipose
tissue by reducing local conversion of inactive cortisone to
active cortisol by using an inhibitor of the enzyme 11-
hydroxysteroid dehydrogenase type 1 (11-HSD1) (12, 35).
However, the magnitude of effect on glycemic control after 3
mo of 11-HSD1 inhibition in unselected patients with Type 2
diabetes was small. Recently, it has been shown that a selective
11-HSD1 inhibitor lowers liver fat content by 2% after 3
mo administration to nondiabetic subjects with liver fat content
5.56% (37), raising the possibility that targeting antigluco-
corticoid therapy at individuals with NAFLD may usefully
stratify higher responders to 11-HSD1 inhibitors.
To investigate the metabolic effects of reducing cortisol
action in individuals with Type 2 diabetes we have tested the
effects of acutely reducing cortisol action on the key metabolic
pathways regulated by insulin. We used a “glucocorticoid
blockade” approach as previously reported (40), by combining
a GR antagonist (RU38486, mifepristone) with a cortisol
biosynthesis inhibitor (metyrapone). Given the potential effect
of glucocorticoids on pathways promoting NAFLD, we also
quantified liver triglycerides by magnetic resonance spectros-
copy (MRS), so that we could infer from a subgroup analysis
whether patients with a high liver fat content are more sensitive
to glucocorticoid blockade.
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MATERIALS AND METHODS
Participants. Fourteen patients with Type 2 diabetes were recruited
from our hospital diabetes clinic. Given the abortifacient properties of
mifepristone, and to avoid the influence of gender on glucocorticoid
signaling, only male patients were studied. Inclusion criteria included:
age 20–70 yr; HbA1c 8% (64 mmol/mol); BMI 40 kg/m2;
negative tests for hepatitis B and C; general health good; normal
screening blood tests (full blood count, renal function, electrolytes,
thyroid function, ferritin); alcohol intake 20 units/wk; no medica-
tions known to increase liver fat, e.g., nucleoside analogs, methotrex-
ate and amiodarone; no medications known to interfere with lipolysis,
e.g., beta blockers; and no glucocorticoid use in the last 6 mo. All
patients were receiving treatment with a single oral antidiabetic agent
(metformin) and primary prevention with a statin. Importantly, neither
metformin (29) nor statins (19) influence fatty acid turnover. Fat mass
was measured by bioimpedance [body fat monitor BF302, OMRON
Healthcare (UK), Henfield, UK]. Local ethical committee approval
and written, informed consent were obtained.
Study design and protocol. Participants entered a two-phase ran-
domized double-blinded placebo-controlled crossover study of gluco-
corticoid blockade. In the active phase, subjects took 400 mg
RU38486 (mifepristone, Exelgyn, Henley-on-Thames, UK) and 1 g of
metyrapone (metopirone, Alliance Pharmaceuticals, Chippenham,
UK) at 2300 the evening before and at 0800 on the morning of the
study, as previously described (40). Study visits were separated by a
washout period of at least 2 wk.
On each study day, subjects attended the clinical research facility at
0800 following an overnight fast. Subjects were asked to refrain
from vigorous exercise and alcohol for 48 h prior to the study and
maintain their normal diets. Studies were performed in a temperature-
controlled room and subjects were studied in light clothing, with free
access to water. The protocol is shown in Fig. 1. “Arterialized” blood
samples were collected from a heated hand by using a 20-gauge
intravenous catheter inserted in retrograde fashion in a dorsal hand
vein and kept patent by infusion of 0.9% saline. Two additional
intravenous cannulae were inserted into the contralateral arm for
infusion of insulin, 20% dextrose, and tracers. Subjects received
primed infusions of 1,1,2,3,3-2H5-glycerol (1.6 mol/kg for 1 min,
then 0.11 mol·kg1·min1) and 6,6-2H2-glucose (17.6 mol/kg for
1 min, then 0.22 mol·kg1·min1), as well as 13C1-palmitate infused
at 0.04 mol·kg1·min1. Given the short time required to reach
steady state with the palmitate tracer, a priming dose was not required
and the palmitate infusion was interrupted during from 90–150 min to
reduce the volume of 20% albumin infused. Blood samples were taken
at baseline, between 60–90 min, and at 210–240 min, the latter during
the final 30 min of a low-dose (10 mU·m 2·min1) hyperinsuline-
mic-euglycemic clamp to investigate suppression of lipolysis and
endogenous glucose production. The insulin infusion was primed at
Table 1. Baseline characteristics and fasting plasma biochemical indexes of study participants with high vs. low liver fat
All Patients High Liver Fat Low Liver Fat
Number of patients 14 7 7
Liver fat, % 13.7 	 3.2 23.0 	 3.9a 4.4 	 0.8
Age, yr 58.6 	 1.7 59.3 	 2.6 58.0 	 2.2
Weight, kg 97.6	 3.4 101.8 	 5.1 93.0 	 4.4
Body mass index, BMI, kg/m2 31.9 	 1.2 34.2 	 2 29.7 	 1.1
Waist circumference, cm 110.4	 2.5 114.7 	 3.6 106.2 	 3.0
Fat mass, kg 30.0 	 2.1 33.6 	 3.1 26.5 	 2.2
Fat-free mass, kg 67.7	 1.6 68.2 	 2.4 67 	 2.4
Time since diagnosis of diabetes, yr 5.3 	 1.0 4.8 	 1.4 5.8 	 1.6
HbA1c, % [mmol/mol] 6.8	 0.2 (51 	 2.2) 7.0	 0.2 (53 	 2.2) 6.5	 0.4 (48 	 4.4)
ALT, IU/l 40.9	 2.7 45.1 	 3.4 36.6 	 3.8
ALP, IU/l 74.5	 4.7 79.4 	 7.2 69.6 	 6.0
GGT, IU/l 21.9	 6.1 18.3 	 8.9 26.2 	 8.8
Total cholesterol, mmol/l 3.9	 0.1 4.0 	 0.1 3.8 	 0.17
Triglycerides, mmol/l 1.9	 0.3 2.2 	 0.5 1.6 	 0.29
HDL cholesterol, mmol/l 1.0	 0.5 1.0 	 0.1 1.0 	 0.03
LDL cholesterol, mmol/l 2.0	 0.2 1.8 	 0.3 2.1 	 0.2
Total-to-HDL cholesterol ratio 3.9	 0.2 4.0 	 0.3 3.7 	 0.2
Results are mean	SE. Groups were compared using independent sample t-tests (equal variances not assumed): aP  0.01. ALT, alanine aminotransferase;
ALP, alkaline phosphatase; GGT, gamma glutamyltransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Fig. 1. Study protocol. The insulin infusion was primed at 20
mU·m 2·min1 for 10 min. Asterisks mark time when breath
sample was taken.
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20 mU·m 2·min1 for 10 min, and euglycemia was maintained by a
variable-rate infusion of 20% dextrose if necessary. Breath samples
were collected immediately before and after an indirect calorimetry
hood was applied by use of sealable glass vials (Exetainers, PDZ,
Cheshire, UK). Because of a technical problem, the second palmitate
infusion was not administered during a single visit for one volunteer.
Each subject emptied his bladder at 0800 and a timed urine
collection was performed during the study visit. Aliquots of urine
were stored at 20°C and urine nitrogen content determined by the
microkjeldahl method (13). Blood was collected in lithium heparin
tubes on ice and promptly centrifuged, and plasma was stored at
80°C until analysis.
Magnetic resonance spectroscopy. On another occasion, all sub-
jects underwent proton MRS to quantify intrahepatic triglycerides.
Spectra corresponding to water and the methylene [-(CH2)n-] compo-
nent of intracellular lipid were obtained and the hepatic fat fraction
content calculated as described by Seppala-Lindroos et al. (36) and
Szczepaniak et al. (38). Patients were divided into two equal groups
based on the median hepatic fat fraction (8.9%): high liver fat
(triglyceride content 10.9%) and low liver fat (6.9%).
Preparation of stable isotope tracer infusions. Stable isotopes were
purchased from Cambridge Isotopes Limited (CK gas, Hook, UK). All
infusates were passed through a 0.22-m filter (Millipore, Watford,
UK) before infusion. The 13C1-palmitate infusion was prepared by
dissolving its potassium salt in heated water, prior to dissolving in
20% human albumin solution (Zenalb, Scottish National Blood Trans-
fusion Service). 1,1,2,3,3-2H5-glycerol and 6,6-2H2-glucose were dis-
solved in 0.9% saline.
Tracer analysis. To determine isotopic enrichment, plasma FFAs
were extracted and derivatized to their methyl esters and analyzed on
a ThermoFinnigan Voyager gas chromatograph mass spectrometer
(GCMS) with an Agilent HP-Innowax column (30 m, 0.320 mm, 0.25
m) operated in electron impact (EI) ionization mode (70 eV).
Source, interface, and injection temperatures were 200, 250, and
260°C, respectively, with selective ion monitoring of molecular ions
with m/z 270, 271, 284, corresponding to [M
0] and [M
1] isoto-
pomers of methyl palmitate and the methyl heptadecanoate internal
standard. Glucose and glycerol isotopomers were derivatized to glu-
cose pentacetate and glycerol triacetate, respectively, by use of pyri-
dine:acetic anhydride (1:1 vol/vol) prior to analysis using the same
column and GCMS in negative chemical ionization mode. Dilution
was required for analysis of glucose, with selective ion monitoring at
m/z of 287 and 289, corresponding to [M
0] and [M
2] fragments of
glucose pentacetate. [M
0] and [M
5] isotopomers of glycerol
triacetate were measured at m/z of 217 and 222, respectively. Glycerol
concentrations were determined by GCMS using butanetriol as an
internal standard. RU38486 levels were measured as previously de-
scribed (40). Breath 13CO2 enrichment was measured by isotope ratio
mass spectrometry (IRMS). An AP2003 IRMS (Analytical Precision,
Northwich, UK) was used to measure 13C abundance in each sample
with respect to a CO2 reference gas that had been calibrated against an
international reference.
Tracer kinetic calculations. The rate of appearance (Ra) of palmi-
tate and glycerol was determined by using Steele’s equation as applied
to steady state, i.e., Ra  tracer infusion rate/TTR, where the TTR is
the isotopic enrichment determined by GCMS expressed as the
tracer-to-tracee ratio. Isotopic enrichment was deemed to be at steady
state if the slope of the TTRs over time, as determined by linear
regression, did not significantly differ from zero in each treatment
group. Results were expressed per kilogram of fat-free mass (FFM).
The Ra of FFAs was calculated by multiplying the Ra of palmitate
by the ratio of plasma FFAs:palmitate (30). Adipose tissue insulin
sensitivity was estimated from the percentage suppression from base-
line of the Ra of FFAs and glycerol during hyperinsulinemia. Whole
body rates of fatty acid reesterification were assessed by using the
formula Ra of FFAs  rate of FFA oxidation (determined by indirect
calorimetry). Negative calculated values, including percentage sup-
pression, were assigned a value of zero.
The percentage of the infused palmitate tracer oxidized was calcu-
lated by using the equation (ECO2 * V˙ CO2)/(F * C), where ECO2 is the
enrichment of expired CO2 (corrected for background abundance),
V˙ CO2 is the flow rate of expired CO2, F is the tracer infusion rate, and
C is the bicarbonate correction factor (81%) taking into account
nonexcreted carbon. Plasma-derived fatty acid oxidation was calcu-
lated by using the equation Ra FFAs * % palmitate oxidized (3).
The Ra of glucose was calculated in basal samples by using
Steele’s equation modified for the nonsteady state, with a pool fraction
of 0.65 and a volume of distribution of 125 ml/kg. Steady-state
calculations were used during the final 210- to 240-min sampling
period. The rate of endogenous glucose production (EGP) was calcu-
lated by subtracting the average glucose infusion rate (GIR) during the
final 30 min of the low-dose clamp from the measured Ra of glucose.
Hepatic insulin sensitivity was estimated as the percentage suppres-
sion from baseline of EGP during low-dose hyperinsulinemia. The
hepatic insulin resistance index, an alternative validated measure of
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Fig. 2. Effects of glucocorticoid blockade (GCB) on plasma ACTH and cortisol. The effect of GCB on plasma ACTH (A) and cortisol (B) levels in patients with
Type 2 diabetes and high or low liver fat (n  7/group). Results are means 	 SE. Effects of glucocorticoid blockade and/or liver fat were analyzed by use of
a generalized linear model for repeated measures with liver fat as a between-subjects factor. aGCB increased ACTH in all subjects (P  0.0001) with no effect
of liver fat or insulin/time. bCortisol levels changed over time (P  0.005; P  0.01 for 0 vs. 90 min and P  0.05 for 90 vs. 240 min on least significant
difference post hoc testing) and tended to decrease with glucocorticoid blockade (P  0.075 for glucocorticoid blockade). cP  0.05 for an interaction of
glucocorticoid blockade with time/insulin.
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hepatic insulin sensitivity for glucose metabolism, was calculated by
multiplying the basal Ra glucose by the insulin concentration (28).
M values, or mean GIRs (mol·kg FFM1·min1) during the final
30 min of the hyperinsulinemic clamp, were corrected for steady-state
insulin concentrations (nmol/l) to provide an index of peripheral
insulin sensitivity (M/I). The insulin clearance rate (l·m 2·min1)
was calculated by dividing the insulin infusion rate (mU·m 2·min1)
by the steady-state insulin concentration (mU/l) during the final
sampling period.
Indirect calorimetry. A ventilated canopy indirect calorimeter (Eu-
ropa Gas Exchange Monitor, NutrEn Technology, Cheshire, UK) was
used during the three 30-min sampling periods. Rates of fat oxidation
were calculated by use of published stoichiometric equations and
multiplied by a factor of three to convert to fatty acid oxidation on the
basis that 1 mol of triglyceride contains 3 mol of FFAs (14).
Other biochemical assays. ELISA kits were used to determine
plasma insulin (DRG Instruments, Marburg, Germany), ACTH
(Biomerica), and cortisol (DRG Instruments). Plasma FFAs were mea-
sured by a colorimetric assay (Zen Bio, Research Triangle Park, NC) and
glucose was measured by the glucose oxidase method.
Statistical analysis. An a priori power calculation showed that a
group size of n  8 would be sufficient to detect 30% differences in
tracer turnover with 80% power to P  0.05. Thus n  14 per group
is generously powered to detect the primary end points of effects of
glucocorticoid blockade. The secondary analysis, testing for differ-
ences in effects of glucocorticoid blockade in patients with high or
low liver fat content, is exploratory. Results are shown as means 	
SE. Baseline characteristics of patients with high and low liver fat
were compared via independent sample t-tests. When comparing a
single variable, e.g., fasting glucose, the effect of glucocorticoid
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Fig. 3. Metabolic effects of glucocorticoid blockade. Effects of glucocorticoid blockade in high and low liver fat subgroups on plasma glucose concentration (A),
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blockade in individuals with high and low fatty liver was determined
by use of a generalized linear model for repeated measures. Similarly,
when comparing measurements at repeated time points, e.g., Ra of
FFAs before and during hyperinsulinemia, a generalized linear model
was used to determine the effects of glucocorticoid blockade and
insulin (both within-subject variables), and liver fat (a between-
subjects variable), and any interactions determined by multivariate
testing and tests of within-subject effects by use of SPSS (IBM).
RESULTS
Baseline characteristics. Table 1 shows baseline patient char-
acteristics, including intrahepatic triglyceride content of the high
and low liver fat subgroups. There were trends for higher body
weight, fat mass, and waist circumference in individuals with high
liver fat, but age, time since diagnosis of diabetes, and biochem-
ical parameters were similar. There was no significant difference
in metformin dose between subgroups (data not shown).
ACTH and cortisol levels. Glucocorticoid blockade in-
creased plasma ACTH (Fig. 2A), whereas metyrapone pre-
vented any compensatory increase in plasma cortisol (Fig. 2B)
and produced a modest but nonsignificant overall reduction in
cortisol levels (P  0.075). ACTH levels were stable through-
out, whereas, after an initial fall, cortisol levels increased
toward the end of each study day, moreso in those receiving
glucocorticoid blockade (P  0.05 for an interaction between
glucocorticoid blockade and time). This suggests the effect of
metyrapone may have declined by the end of the protocol,
whilst importantly, the GR blocking effect of RU38486 was
maintained throughout. ACTH and cortisol levels were similar
in patients with high and low liver fat after both placebo and
glucocorticoid blockade (Fig. 2B). RU38486 concentrations
were similar following glucocorticoid blockade (2.8 	 0.5 vs.
2.8 	 0.5 mol/l in high vs. low liver fat groups), and
undetectable following placebo.
Glucose metabolism. Plasma glucose profiles, and glucose
TTRs are shown in Fig. 3, A and B, and results of kinetic
calculations in Tables 2 and 3. During the low-dose insulin
infusion there was a modest but significant rise in insulin
levels, which suppressed EGP.
Glucocorticoid blockade lowered fasting insulin and glucose
concentrations, as well as insulin levels throughout the proto-
col, although there was no significant increase in insulin
clearance, and plasma glucose was successfully maintained at
similar levels during the final 30 min of the low-dose hyper-
insulinemic clamp. Glucocorticoid blockade decreased EGP
(P  0.05), reducing the corresponding hepatic insulin resis-
tance index, but had no influence on glucose oxidation.
None of the effects of GC blockade was measurably differ-
ent between high and low liver fat subgroups, i.e., there were
no interactions between glucocorticoid blockade and liver fat
in the general linear model analyses. However, individuals
with Type 2 diabetes and high liver fat had higher fasting
glucose and insulin levels, lower GIRs, and a corresponding
higher M/I index and sustained higher insulin levels throughout
the protocol than those with low liver fat. Glucose levels
during the final 30 min of the clamp and insulin clearance did
not differ between liver fat subgroups. As a result, although
EGP and its suppression by insulin did not significantly differ
between subgroups, the hepatic insulin resistance index was
higher in the high liver fat subgroup. High liver fat had no
influence on basal rates of glucose oxidation but was associated
with a failure to maintain rates of glucose oxidation during
hyperinsulinemia (Table 3).
Fatty acid metabolism. Plasma glycerol and FFA concentra-
tions and TTRs are displayed in Fig. 3, C–F, and statistical
analyses of the mean values in steady state with and without
insulin infusion are shown in Tables 4 and 5. Low-dose insulin
infusion suppressed glycerol and FFA concentrations, the Ra
of glycerol and Ra FFAs in plasma, and rates of FFA oxidation
and reesterification.
Glucocorticoid blockade had modest effects on fatty acid
metabolism, with little effect on baseline indexes, but potenti-
ated insulin-mediated suppression of FFA concentrations and
Ra glycerol, also tending to increase suppression of Ra FFAs.
Glucocorticoid blockade had no effects on FFA oxidation or
reesterification. There were no interactions between glucocor-
ticoid blockade and liver fat on measures of glycerol or FFA
turnover to suggest any differential effect of glucocorticoid
blockade in patients with high liver fat.
The high liver fat subgroup showed striking differences in
fatty acid metabolism compared with patients with low liver
fat, most evident in their responsiveness to low-dose insulin
Table 2. Effects of glucocorticoid blockade on glucose
metabolism in all subjects
All Patients (n  14) P Value
Effect of
GCBGCB Placebo
Plasma glucose, mmol/la
Fasting 5.8 	 0.2 7.1 	 0.3 0.0001
Hyperinsulinemia 4.6	 0.1 4.8 	 0.2 0.30
Plasma insulin, pmol/le
Fasting 78.6 	 16.8 102.6 	 17.7 0.05b
Prolonged fasting 59.3	 10.2 74.2 	 11.3
0.05cHyperinsulinemia 100.1	 8.8 114.2 	 11.0
Insulin clearance, l·m2·min1 0.78 	 0.08 0.70 	 0.07 0.10
M value, mol·kg FFM·min1 4.7 	 1.0 3.3 	 1.2 0.28
M/I index, mol·kg
FFM1·min1·nmol1·l1
59.4 	 15.0 43.8 	 21.0 0.46
EGP, mol·kg FFM1·min1d
Prolonged fasting 16.5	 1.8 19.0 	 2.3 0.05Hyperinsulinemia 10.7	 1.4 12.4 	 1.1
% Suppression 34.9 	 6.4 29.3 	 6.2 0.41
Hepatic IR index,
pmol·l1·mmol1·kg
FFM1·min1
1.0 	 0.2 1.4 	 0.2 0.001
Glucose oxidation by indirect
calorimetry, mol·kg
FFM1·min1e
Fasting 13.7 	 1.2 13.5 	 1.2
0.60Prolonged fasting 10.5	 0.9 11.3 	 0.6
Hyperinsulinemia 9.4	 1.1 10.5 	 1.4
Results are means 	 SE. Fasting refers to mean of measurements from 30
to 0 min, Prolonged fasting to 
60 to 90 min, and Hyperinsulinemia to 
210
to 240 min in the protocol. EGP, endogenous glucose production; FFM,
fat-free mass; GCB, glucocorticoid blockade; M value; mean glucose infusion
rate during 210–240 min; IR, insulin resistance. To determine any overall
effect of glucocorticoid blockade, at all time points measured, in patients with
and without increased liver fat, data were analyzed using a generalized linear
model for repeated measures, with liver fat as a between-subjects variable. P
values are derived from the generalized linear models for the effects of GCB
and/or of liver fat. Footnotes denote any additional significant interactions of
glucocorticoid blockade, liver fat, and insulin infusion (or time) as determined
by multivariate testing and tests of within-subject effects. aFasting and hyper-
insulinemic plasma glucose concentrations were analyzed separately. bP value
for analysis of fasting insulin concentrations alone. cP 0.05 for an interaction
between GCB or liver fat and time/insulin. dP  0.01 for an effect of
insulin/time. eP  0.001 for an effect of insulin/time.
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infusion, with impaired suppression of FFA and glycerol con-
centrations and rates of appearance, as well as suppression of
fatty acid oxidation and reesterification.
DISCUSSION
These detailed metabolic studies show that blocking cortisol
action in patients with Type 2 diabetes has significant meta-
bolic effects, leading to insulin sensitization in both adipose
tissue and the liver, with associated reductions in fasting
plasma glucose concentrations and hyperinsulinemia. These
effects appear to be independent of baseline liver fat content,
since similar effects of glucocorticoid blockade were observed
in patients with high or low liver fat, albeit this inference is
drawn from a secondary subgroup analysis. In addition, the
measurements made at baseline and during the placebo phase
allowed us to detail the metabolic differences between patients
with and without high liver fat content; this is the first such
report among patients with Type 2 diabetes. The high liver fat
group exhibited similar manifestations of more severe insulin
resistance for both fatty acid and glucose metabolism than
patients with low liver fat, as previously reported in nondia-
betic patients with NAFLD (5, 9, 11).
Although there are extensive previous studies describing the
effects of elevated glucocorticoids on metabolism, very few
have addressed the consequences of reducing cortisol action,
particularly in the context of diabetes (reviewed in Refs. 1, 25).
In studies in healthy subjects using limited assessments of
metabolic flux, glucocorticoid receptor antagonism with
RU38486 has been shown to achieve substantial drug levels in
adipose tissue (17) and to lower serum triglycerides (31, 40)
and reduce EGP (15). We show that glucocorticoid blockade
was technically successful in elevating ACTH and preventing
significant rebound hypercortisolemia (Fig. 2), resulting in
lower fasting glucose and insulin levels and improved insulin
sensitivity at multiple sites.
The influence of glucocorticoids on hepatic gluconeogenesis
is well recognized, although the mechanisms are incompletely
defined, with both indirect effects of FFAs and direct effects of
cortisol potentially promoting gluconeogenesis (reviewed in
Refs. 1, 25). Here, the lack of any reduction in basal FFA
turnover associated with the fall in EGP suggests direct effects
of glucocorticoids on the liver prevail, in keeping with recent
evidence using 11-HSD1 inhibitors in dogs (10).
The mechanism for the improvement in adipose tissue insu-
lin sensitivity following glucocorticoid blockade is complex. In
vitro data suggest that glucocorticoids have a permissive effect
to increase turnover between FFAs and triglyceride in adi-
pocytes by inducing both lipolysis and reesterification (25, 33).
In vivo studies have suggested that the net influence of cortisol
on lipolysis is highly dependent on prevailing insulin concen-
trations: cortisol has a more pronounced effect to induce
lipolysis when insulin levels are low, e.g., during a pancreatic
clamp or overnight, whereas rates of lipolysis may be reduced
by cortisol when there is compensatory hyperinsulinemia, e.g.,
in Cushing’s syndrome. These observations are based on ele-
vated cortisol levels, however, and cannot necessarily be ex-
trapolated when reducing physiological cortisol action. We
found that glucocorticoid blockade increased insulin-mediated
suppression of glycerol release, with a similar trend for FFA
turnover, despite somewhat lower plasma insulin concentra-
tions, but we did not find effects on reesterification of FFA to
triglycerides or in the balance of oxidation of FFAs or glucose.
Previous studies employing tracers in patients without dia-
betes have shown a number of metabolic abnormalities asso-
Table 3. Effects of glucocorticoid blockade on glucose metabolism in subjects classified by liver fat content
High Liver Fat (n  7) Low Liver Fat (n  7) P Values
GCB Placebo GCB Placebo
Effect of
GCB
Effect of
liver fat
Plasma glucose, mmol/la
Fasting 6.5 	 0.1 7.8 	 0.4 5.1 	 0.4 6.4 	 0.4 0.0001 0.01
Hyperinsulinemia 4.8	 0.1 5.1 	 0.4 4.5 	 0.1 4.6 	 0.2 0.30 0.27
Plasma insulin, pmol/le
Fasting 121 	 33 149 	 35 36 	 6 56 	 7 0.05b 0.05b
Prolonged fasting 87	 20 106 	 22 31 	 4 42 	 5
0.05c 0.05cHyperinsulinemia 113	 14 135 	 19 87 	 11 93 	 11
Insulin clearance, l·m2·min 0.67 	 0.11 0.58	 0.1 0.89 	 0.12 0.82	 0.10 0.10 0.12
M value, mol·kg FFM1·min1 2.3 	 1.3 0.7 	 0.4 7.1 	 1.4 5.9 	 2.3 0.28 0.05
M/I index, mol·kg FFM1·min1·nmol1·l1 25.2 	 16.2 7.4	 6.0 93.7 	 25.3 80.3	 41.5 0.46 0.05
EGP, mol·kg FFM1·min1d
Prolonged fasting 17.2	 2.1 19.3 	 2.4 15.7 	 2.9 18.7 	 3.8 0.05 0.35Hyperinsulinemia 12.9	 1.3 14.0 	 1.4 8.5 	 2.5 10.8 	 1.6
% Suppression 23.0 	 4.7 25.5 	 4.4 45.8 	 12.1 31.8	 11.7 0.41 0.20
Hepatic IR index, pmol·l1·mmol1·kg FFM1·min1 1.5 	 0.4 2.0 	 0.4 0.5 	 0.1 0.7 	 0.1 0.001 0.05
Glucose oxidation by indirect calorimetry, mol·kg FFM1·min1e
Fasting 15.0 	 2.1 13.8 	 1.3 12.4 	 1.4 13.2 	 2.0
0.60 0.71cProlonged fasting 11.3	 1.7 11.0 	 1.0 9.7 	 0.5 11.7 	 0.7
Hyperinsulinemia 8.8	 0.9 7.7 	 1.7 10.1 	 2.0 13.3 	 2.1
Results are means 	 SE. Fasting refers to mean of measurements from 30 to 0 min, Prolonged fasting to 
60 to 90 min, and Hyperinsulinemia to 
210
to 240 min in the protocol. To determine any overall effect of glucocorticoid blockade, at all time points measured, in patients with and without increased liver
fat, data were analyzed using a generalized linear model for repeated measures, with liver fat as a between-subjects variable. P values are derived from the
generalized linear models for the effects of GCB and/or of liver fat. Footnotes denote any additional significant interactions of glucocorticoid blockade, liver fat,
and insulin infusion (or time) as determined by multivariate testing and tests of within-subject effects. aFasting and hyperinsulinemic plasma glucose
concentrations were analyzed separately. bP value for analysis of fasting insulin concentrations alone. cP  0.05 for an interaction between GCB or liver fat and
time/insulin. dP  0.01 for an effect of insulin/time. eP  0.001 for an effect of insulin/time.
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ciated with liver fat, including increased FFA and glycerol
turnover, impaired suppression of lipolysis by insulin, in-
creased hepatic triglyceride export, de novo lipogenesis, and
hepatic insulin resistance (5, 9, 11). Similar metabolic abnor-
malities characterize patients with Type 2 diabetes (2, 21),
although our results show clear differences among those with
Type 2 diabetes according to whether they have high or low
liver fat. These findings suggest that propensity to liver fat
accumulation in Type 2 diabetes is associated with hyperinsu-
linemia and with more marked adipose, hepatic, and peripheral
insulin resistance. Patients with Type 2 diabetes and high liver
fat also had impaired metabolic flexibility, with a reduced
ability to switch from fat to glucose oxidation during hyperin-
sulinemia.
The lack of any differential effect of glucocorticoid blockade
in the subgroup with high liver fat was unexpected, although
this inference is drawn from a subgroup analysis with limited
statistical power to detect subtle differences in response be-
tween groups. We defined high liver fat on the basis of the
median observed hepatic fat fraction in our participants (7%)
rather than the published criteria of 6.1% (5.5% corrected
intrahepatic triglyceride content per 100 g wet liver tissue)
derived from nondiabetic individuals with no risk factors for
NAFLD (39) or the inclusion criteria (5.56%) for a recently
published study of 11-HSD1 inhibition in NAFLD (37).
Since liver fat is continuously distributed it is arguably an
oversimplification to regard any cutoff value as definitive, and
our definition is consistent with the median liver fat content
reported among patients with Type 2 diabetes in Edinburgh,
where our participants were recruited (42). By comparing
subgroups with a high vs. arguably a low-moderate liver fat
content it is possible we may have underestimated differences
in the high liver fat subgroup. MRS scans were performed at
the time of screening, on average 51 days before the tracer
studies, but the intrasubject coefficient of variation of liver fat
measurements has previously been estimated to be low (8.5%)
(39) and there was no change in body weight between study
visits. There was no effect of liver fat on ACTH or RU38486
levels to suggest altered efficacy of the drug regimen. At face
value, these findings suggest that whereas tissue-specific
changes in glucocorticoid metabolism may be important mod-
ulators of liver fat, they may not be the primary driver of
increased liver fat in Type 2 diabetes. Nevertheless, a number
of metabolic parameters were improved, and the lowering of
plasma insulin by glucocorticoid blockade may, of itself, be
advantageous since in NAFLD, despite resistance to the effect
of insulin to suppress gluconeogenesis, sensitivity to promo-
tion of de novo lipogenesis is retained (24); glucocorticoid
blockade may therefore also reduce hepatic lipogenesis, al-
though this was not tested in our acute intervention study.
As with all detailed metabolic studies there are technical limi-
tations to consider. The discrepancy between the hepatic insulin
resistance index and the percentage suppression of EGP may have
been due to omission of D2-glucose from the 20% dextrose
infusion. The plasma-derived FFA oxidation results need to be
interpreted with caution because we did not prime the bicarbonate
pool, although the results closely mirror the indirect calorimetry
data. The high liver fat subgroup also tended to be more obese; we
expressed our tracer data, however, per kilogram of fat-free mass,
which is thought most closely to represent the flux of FFAs
toward lean tissues, including the liver (22). All participants were
receiving metformin, which might interact with glucocorticoid
blockade but suggests pragmatically that therapies to lower cor-
tisol may be of benefit in patients currently on optimized oral
antidiabetic therapy.
In this acute intervention study we demonstrated that reduc-
ing glucocorticoid action appears to improve insulin sensitivity
at a number of sites in patients with Type 2 diabetes. These
actions may contribute to improvements in a range of meta-
bolic variables following longer term reductions in glucocor-
ticoid action resulting from inhibition of 11-HSD1 (12, 35,
37). Our results suggest glucocorticoid blockade is equally
Table 4. Effects of glucocorticoid blockade on fatty acid
metabolism in all subjects
All Patients (n  14) P Value
Effect of
GCBGCB Placebo
Plasma glycerol, mol/la
Fasting 53	 8 48 	 7
0.21Prolonged fasting 58	 7 52 	 7
Hyperinsulinemia 36	 7 36 	 6
Plasma FFAs, mmol/la
Fasting 653	 64 561 	 35
0.06cProlonged fasting 740	 80 592 	 40
Hyperinsulinemia 386	 68 374 	 45
Ra Glycerol, mol·kg FFM1·min1a
Prolonged fasting 4.7	 0.4 4.2 	 0.6 0.49cHyperinsulinemia 3.3	 0.3 3.3 	 0.3
% Suppression 29.9	 2.7 21.6 	 3.7 0.05
Ra FFAs, mol·kg FFM1·min1b
Prolonged fasting 9.6	 4.2 7.6 	 1.0 0.27Hyperinsulinemia 4.5	 0.9§ 4.6 	 0.6
% Suppression 49.1	 7.9§ 35.2 	 7.0 0.06
FFA oxidation by indirect
calorimetry, mol·kg
FFM1·min1b
Fasting 3.3	 0.3 3.2 	 0.2
0.35Prolonged fasting 4.1	 0.2 3.8 	 0.3
Hyperinsulinemia 4.3	 0.3 3.9 	 0.4
% Suppression 10.7	 4.8 13.6 	 5.2 0.65
Plasma FFA oxidation§§, mol·kg
FFM1·min1b
60 min 0.41 	 0.06 0.33 	 0.06
0.77c90 min 0.54 	 0.06 0.48 	 0.07210 min 0.41 	 0.05 0.41 	 0.06
240 min 0.51 	 0.06 0.50 	 0.07
% Suppression, 90 vs. 210 min 26.7 	 7.6 20.5 	 7.2 0.41
FFA reesterification, mol·kg
FFM1·min1b
Prolonged fasting 5.5	 1.2 3.8 	 1.0 0.48Hyperinsulinemia 1.2	 0.8 1.2 	 0.8
% Suppression 79	 11 70 	 11 0.63
Data are means 	 SE. N  7/group except where §n  6, §§n  4–6.
Fasting refers to measurements at 30 to 0 min, Prolonged fasting to 
60 to
90 min, and Hyperinsulinemia to 
210 to 240 min in the protocol; %
Suppression describes comparison of hyperinsulinemic with basal conditions.
FFM, fat-free mass; GCB, glucocorticoid blockade; NS, not significant; Ra,
rate of appearance. To determine any overall effect of glucocorticoid blockade,
at all time points measured, in patients with and without increased liver fat,
data were analyzed using a generalized linear model for repeated measures,
with liver fat as a between-subjects variable. P values are derived from the
generalized linear models for the effects of GCB and/or of liver fat. Footnotes
denote any additional significant interactions of glucocorticoid blockade, liver
fat and insulin infusion (or time) as determined by multivariate testing and tests
of within-subject effects. aP  0.0001 for an effect of insulin/time. bP  0.01
for an effect of insulin/time. cP  0.05 for an interaction of GCB or liver fat
with insulin/time. dP  0.01 for an interaction of GCB or liver fat with
insulin/time. eP  0.001 for an interaction of GCB or liver fat with insulin/time.
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efficacious in individuals with Type 2 diabetes and increased
liver fat, despite the multiple sites of greater insulin resistance
found in these individuals.
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